

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF

WAGNER ET AL.

INTERNATIONAL APPLICATION NO: PCT/EP2005/003663

FILED: 7 APRIL 2005

U.S. APPLICATION NO: Not yet known

35 USC §371 DATE: Herewith

FOR: PROTEIN KINASE C INHIBITORS FOR THE TREATMENT OF
AUTOIMMUNE DISEASES AND OF TRANSPLANT REJECTION

MS: Amendment

Commissioner for Patents

PO Box 1450

Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is being filed within three months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 of the international application. Therefore, no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.


In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

The listed references were cited in the international stage search report. Since these references are of record in the instant PCT application PCT/EP2005/003663, copies are not enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(862) 778-7909


Thomas R. Savitsky
Attorney for Applicants
Reg. No. 31,661

Date: *October 5, 2006*

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
33714-US-PCT
APPLICATION NO.
Not yet known
APPLICANT
WAGNER ET AL.
FILING DATE

Group

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA	5,545,636	8/13/96	Heath, Jr. et al.	514	214	10/18/94
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AM	03/082859	10/9/03	WO			<input type="checkbox"/>	<input type="checkbox"/>
	AN	03/104222	12/18/03	WO			<input type="checkbox"/>	<input type="checkbox"/>
	AO	98/11105	3/19/98	WO			<input type="checkbox"/>	<input type="checkbox"/>
	AP	0 470 490	2/12/92	EP			<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AR	Bradshaw D et al., "Therapeutic Potential of Protein Kinase C Inhibitors". Agents and Actions, Birkhaeuser Verlag, Basel, CH, Vol. 38, pp. 135-147, (1993).
AS	Nixon J S et al., "Novel, potent and selective inhibitors of protein kinase C show oral anti-inflammatory activity.", Drugs Under Experimental And Clinical Research, Bioscience Ediprint Inc., Vol. 17, no. 8, pp. 389-393, (1991).
AT	Harris W et al., "Recent developments in protein kinase C inhibitors", Expert Opinion On Therapeutic Patents, United Kingdom, vol. 7, no. 1, pp. 63-68, (1997).

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.